A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Summary
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Heart Failure
Intervention
Cinaciguat (BAY58-2667), Cinaciguat (BAY58-2667), Cinaciguat (BAY58-2667), Placebo
Location
Chicago
Illinois
United States
60610
Status
Recruiting
Source
Bayer
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01064037
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Clinical Trials
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well...
The purpose of this study is to assess a dose titration scheme, of a new drug (BAY 58-2667) given intravenously, to evaluate if this is safe and can help to improve the well-being, symptom...
PubMed Articles
Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.
Nitric oxide (NO) signaling mediates many important physiological processes through the receptor soluble guanylate cyclase (sGC). Under disease conditions sGC heme can be oxidized resulting in NO inse...
Protein kinase G type I (PKGI) plays a critical role in survival signaling of pre- and postconditioning downstream of cardiac cGMP. However, it is unclear whether PKGI exerts its protective effects in...
Soluble Guanylate Cyclase Modulators in Heart Failure.
This review summarizes the role of soluble guanylate cyclase (sGC)-cyclic guanosine 3', 5'-monophosphate pathways in heart failure and several new drugs that modify guanylate cyclase. The sGC activato...
Nitric oxide sensitive guanylyl cyclase (NOsGC) is a heterodimeric enzyme consisting of an alpha and a beta subunit. Two heterodimeric enzymes are known to be important for NO-signalling in humans: al...
Oxidation and Loss of Heme in Soluble Guanylyl Cyclase from Manduca sexta.
Oxidation and loss of heme in soluble guanylyl/guanylate cyclase (sGC), the nitric oxide receptor, is thought to be a major contributor to cardiovascular disease and is the target of compounds BAY 58-...
